RxDoctor Payments Data

Alexander Diaz de Villavilla, MD

Internal Medicine · Providence, RINPI 1548422074

Payments from drug & device makers

$315in general payments, 2019–2025

Across 12 payments — averaging $26.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$150
  • Sanofi-aventis U.S. LLC$35
  • Merck$26
  • Novo Nordisk$18
  • Medline Industries LP$17
  • E.r. Squibb & Sons, L.L.C.$17
  • plus $52 from 4 others

What the payments were for

  • Food & beverage$315100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$315 in reported general payments places this provider in the 65th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$16,856
Medicare patients
67
Services billed
259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$44,492
TrulicityDulaglutide19$27,933
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$19,306
OzempicSemaglutide15$19,229
Repatha SureclickEvolocumab14$13,269
JardianceEmpagliflozin13$10,840
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate28$6,853
Varenicline Tartrate16$4,887
Incruse ElliptaUmeclidinium Bromide13$4,779
Rosuvastatin Calcium286$3,494
Trospium Chloride ErTrospium Chloride16$2,940
Diclofenac Sodium-MisoprostolDiclofenac Sodium/Misoprostol14$2,698
Atorvastatin Calcium168$2,042
Ezetimibe60$1,645
Albuterol Sulfate HfaAlbuterol Sulfate41$1,623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$11$45,86963 claims
GSKTrelegy Ellipta, Incruse Ellipta$16$24,08545 claims
Novo NordiskOzempic$18$19,22915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →